Proteomics International Laboratories Limited is a biological research and drug discovery company. The Company operates in three business units unified by a technology platform: Analytical services, which includes specialist contract research, analytical testing and consultancy; Diagnostics, which includes biomarkers of disease and personalized medicine, and Therapeutics, which includes peptide drug discovery from venoms. The Company focuses on the PromarkerD, a proteomics-derived predictive and diagnostic test for diabetic kidney disease. The Company focuses on its diagnostics portfolio using the Promarker platform, and is investigating proteins associated with endometriosis, mesothelioma and other conditions. The Company has a therapeutic drug discovery program targeting new analgesic (painkilling) and antibiotic drug compounds. The Company also has a laboratory to analyze the make-up of biosimilar drugs as being like-for-like with the brand name drugs they seek to replace.